Suchergebnisse - "Burhenne, Jürgen"

PubPharm (529)

21

Protocol of the IntenSify-Trial : An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

enthalten in: Clinical and translational science | 2023

von Hohmann, N. | Sprick, M. | Pohl, M. | +19

22

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

enthalten in: Clinical pharmacokinetics | 2023

von Muhareb, A. | Blank, A. | Meid, A. | +5

23

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

enthalten in: Nature cancer | 2023

von Zhou, X. | An, J. | Kurilov, R. | +23

24

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

enthalten in: Clinical pharmacokinetics | 2023

von Muhareb, A. | Blank, A. | Meid, A. | +5

25

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

enthalten in: Clinical pharmacokinetics | 2023

von Muhareb, A. | Blank, A. | Meid, A. | +5

26

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

enthalten in: Clinical pharmacokinetics | 2023

von Muhareb, A. | Blank, A. | Meid, A. | +5

27

Quantification of Biologically Active DNA Alkylation in Temozolomide-Exposed Glioblastoma Cell Lines by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry : Method Development and Recommendations for Validation

enthalten in: ACS omega | 2023

von Fresnais, M. | Jung, I. | Klein, U. | +5

28

Desorption Kinetics Evaluation for the Development of Validated Desorption Electrospray Ionization-Mass Spectrometric Assays for Drug Quantification in Tissue Sections

enthalten in: International journal of molecular sciences | 2023

von Fresnais, M. | Liang, S. | Seven, D. | +5

29

Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

enthalten in: Frontiers in pharmacology | 6 April 2023

von Zhu, V. | Burhenne, J. | Weiß, J. | +8

30

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

enthalten in: Neuro-oncology | 2023

von Sigaud, R. | Rösch, L. | Gatzweiler, C. | +26